{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T09:16:41Z","timestamp":1769591801732,"version":"3.49.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2005,5,1]],"date-time":"2005-05-01T00:00:00Z","timestamp":1114905600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2005,5,1]],"date-time":"2005-05-01T00:00:00Z","timestamp":1114905600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinical-colorectal-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Colorectal Cancer"],"published-print":{"date-parts":[[2005,5]]},"DOI":"10.3816\/ccc.2005.n.014","type":"journal-article","created":{"date-parts":[[2008,9,10]],"date-time":"2008-09-10T21:06:10Z","timestamp":1221080770000},"page":"27-36","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Edotecarin: A Novel Topoisomerase I Inhibitor"],"prefix":"10.3816","volume":"5","author":[{"given":"M. Wasif","family":"Saif","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert B.","family":"Diasio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.3816\/CCC.2005.n.014_bib1","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1146\/annurev.bi.54.070185.003313","article-title":"DNA topoisomerases","volume":"54","author":"Wang","year":"1985","journal-title":"Annu Rev Biochem"},{"key":"10.3816\/CCC.2005.n.014_bib2","doi-asserted-by":"crossref","first-page":"3888","DOI":"10.1021\/ja00968a057","article-title":"Plant antitumor agents I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata","volume":"88","author":"Wall","year":"1969","journal-title":"J Am Chem Soc"},{"key":"10.3816\/CCC.2005.n.014_bib3","first-page":"515","article-title":"Phase I clinical trial of weekly and daily treatment with camptothecin sodium (NSC-100880)","volume":"56","author":"Muggia","year":"1972","journal-title":"Cancer Chemother Rep"},{"key":"10.3816\/CCC.2005.n.014_bib4","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/j.1749-6632.1996.tb26372.x","article-title":"Synthesis of CPT-11 (irinotecan hydrochloride trihydrate)","volume":"803","author":"Sawada","year":"1996","journal-title":"Ann N Y Acad Sci"},{"key":"10.3816\/CCC.2005.n.014_bib5","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/j.1749-6632.1996.tb26399.x","article-title":"Clinical trials of irinotecan hydrochloride (CPT, campto injection, topotecan injection) in Japan","volume":"803","author":"Saijo","year":"1996","journal-title":"Ann N Y Acad Sci"},{"key":"10.3816\/CCC.2005.n.014_bib6","doi-asserted-by":"crossref","first-page":"224","DOI":"10.3816\/CLC.2003.n.002","article-title":"A phase II study of topotecan in patients with relapsed small-cell lung cancer","volume":"4","author":"Takeda","year":"2003","journal-title":"Clin Lung Cancer"},{"key":"10.3816\/CCC.2005.n.014_bib7","first-page":"2134","article-title":"Phase I and pharmacokinetic study of DX-8951f (exatecan mesylate), a hexacyclic camptothecin, on a daily-times-five schedule in patients with advanced leukemia","volume":"8","author":"Giles","year":"2002","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CCC.2005.n.014_bib8","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S0960-894X(00)00004-4","article-title":"Synthesis and biological activities of NB-506 analogues modified at the glucose group","volume":"10","author":"Ohkubo","year":"2000","journal-title":"Bioorg Med Chem Lett"},{"key":"10.3816\/CCC.2005.n.014_bib9","first-page":"1316","article-title":"Novel indolocarbazole compound 6-N-formylamino-12,13-dihydro-1,11-dihydroxy-13-(beta-D-glucopyranosyl)-5H-indolo[2,3-a]pyrrolo-[3,4-c]carbazole-5,7(6H)-dione (NB-506): its potent antitumor activities in mice","volume":"55","author":"Arakawa","year":"1995","journal-title":"Cancer Res"},{"key":"10.3816\/CCC.2005.n.014_bib10","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1111\/j.1349-7006.1999.tb00691.x","article-title":"In vivo anti-tumor activity of a novel indolocarbazole compound, J-107088, on murine and human tumors transplanted into mice","volume":"90","author":"Arakawa","year":"1999","journal-title":"Jpn J Cancer Res"},{"key":"10.3816\/CCC.2005.n.014_bib11","first-page":"4271","article-title":"Mode of action of a new indolocarbazole anticancer agent, J-107088, targeting topoisomerase I","volume":"59","author":"Yoshinari","year":"1999","journal-title":"Cancer Res"},{"key":"10.3816\/CCC.2005.n.014_bib12","first-page":"1310","volume":"55","author":"Yoshinari","year":"1995","journal-title":"Cancer Res"},{"key":"10.3816\/CCC.2005.n.014_bib13","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/(SICI)1097-0215(19980105)75:1<145::AID-IJC22>3.0.CO;2-E","article-title":"Sequence-selective DNA cleavage by topoisomerase I poison, NB-506","volume":"75","author":"Fukasawa","year":"1998","journal-title":"Int J Cancer"},{"key":"10.3816\/CCC.2005.n.014_bib14","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/S0960-894X(99)00188-2","article-title":"Synthesis and biological activities of topoisomerase I inhibitors, 6-N-amino analogues of NB-506","volume":"9","author":"Ohkubo","year":"1999","journal-title":"Bioorg Med Chem Lett"},{"key":"10.3816\/CCC.2005.n.014_bib15","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0026-895X(24)26399-9","article-title":"The staurosporine-like compound L-753,000 (NB-506) potentiates the neurotrophic effects of neurotrophin-3 by acting selectively at the TrkA receptor","volume":"56","author":"Pollack","year":"1999","journal-title":"Mol Pharmacol"},{"key":"10.3816\/CCC.2005.n.014_bib16","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1007\/s002800100347","volume":"48","author":"Cavazos","year":"2001","journal-title":"Cancer Chemother Pharmocol"},{"key":"10.3816\/CCC.2005.n.014_bib17","first-page":"2827","article-title":"Identification of breast cancer resistant protein\/mitoxantrone resistance\/placenta-specific, ATPbinding cassette transporter as a transporter of NB-506 and J-107088, topoisomerase I inhibitors with an indolocarbazole structure","volume":"61","author":"Komatani","year":"2001","journal-title":"Cancer Res"},{"key":"10.3816\/CCC.2005.n.014_bib18","first-page":"2806","article-title":"Antitumor activities of a new indolcarbazole substance, NB-506, and establishment of NB-506-resistant cell lines, SBC-3\/NB","volume":"55","author":"Kanzawa","year":"1995","journal-title":"Cancer Res"},{"key":"10.3816\/CCC.2005.n.014_bib19","first-page":"159a","article-title":"Phase II trials of J-107088, a non-camptothecin topoisomerase I inhibitor, in irinotecan naive\/refractory metastatic colorectal cancer","volume":"21","author":"Perez","year":"2002","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.3816\/CCC.2005.n.014_bib20","first-page":"274","article-title":"Phase II efficacy and tolerability of edotecarin (J-107088) in patients with irinotecannaive metastatic colorectal cancer (MCRC)","volume":"22","author":"Nahum","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.3816\/CCC.2005.n.014_bib21","first-page":"2701","article-title":"A new mechanism of acquisition of drug resistance by partial duplication of topoisomerase I","volume":"59","author":"Komatani","year":"1999","journal-title":"Cancer Res"},{"key":"10.3816\/CCC.2005.n.014_bib22","first-page":"173","article-title":"Edotecarin","volume":"7","author":"Denny","year":"2004","journal-title":"Drugs"},{"key":"10.3816\/CCC.2005.n.014_bib23","first-page":"197a","article-title":"Phase I trial of J-107088, a novel topoisomerase I inhibitor, administered once every 21 days","volume":"19","author":"Peck","year":"2000","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.3816\/CCC.2005.n.014_bib24","first-page":"177a","article-title":"A phase-1 study of the novel topoisomerase-I inhibitor J-107088 administered on a multiple-dose schedule","volume":"19","author":"Lewis","year":"2000","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.3816\/CCC.2005.n.014_bib25","first-page":"97a","article-title":"Phase I trial of J-107088, a novel topoisomerase I inhibitor, administered once every 21 days","volume":"21","author":"Yamada","year":"2002","journal-title":"Proc Am Soc Clin Oncol"}],"container-title":["Clinical Colorectal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1533002811701633?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1533002811701633?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T22:58:25Z","timestamp":1761519505000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1533002811701633"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,5]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2005,5]]}},"alternative-id":["S1533002811701633"],"URL":"https:\/\/doi.org\/10.3816\/ccc.2005.n.014","relation":{},"ISSN":["1533-0028"],"issn-type":[{"value":"1533-0028","type":"print"}],"subject":[],"published":{"date-parts":[[2005,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Edotecarin: A Novel Topoisomerase I Inhibitor","name":"articletitle","label":"Article Title"},{"value":"Clinical Colorectal Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.3816\/CCC.2005.n.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2005 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}